[{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longbio Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"LP-003","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Longbio Pharma \/ Qiming Venture Partners","highestDevelopmentStatusID":"12","companyTruncated":"Longbio Pharma \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Longbio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"LP-003","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Longbio Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Longbio Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Longbio Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Longbio Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : LP-003 is the company's next-generation anti-IgE antibody. Currently, it is being evaluated in the early-stage clinical trial studies for the treatment of food allergy.

                          Brand Name : LP-003

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 25, 2024

                          Lead Product(s) : LP-003

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The financing aims to advance the clinical development of the company's lead product LP-003, a best-in-class, anti-IgE antibody, which is being evaluated for Chronic Spontaneous Urticaria.

                          Brand Name : LP-003

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 24, 2024

                          Lead Product(s) : LP-003

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Qiming Venture Partners

                          Deal Size : $1.4 million

                          Deal Type : Series B Financing

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : LP-003 is a novel humanized monoclonal anti-IgE antibody candidate, which is being evaluated for the treatment of patients with chronic spontaneous urticaria.

                          Brand Name : LP-003

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 12, 2024

                          Lead Product(s) : LP-003

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : LP-003 is a novel monoclonal anti-IgE antibody, which is currently being evaluated for the treatment of adults with moderate-to-severe chronic spontaneous urticaria.

                          Brand Name : LP-003

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 25, 2024

                          Lead Product(s) : LP-003

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank